63,015 Shares in REGENXBIO Inc. (NASDAQ:RGNX) Purchased by PDT Partners LLC

PDT Partners LLC acquired a new position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 63,015 shares of the biotechnology company's stock, valued at approximately $487,000. PDT Partners LLC owned 0.13% of REGENXBIO as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in REGENXBIO during the fourth quarter worth about $3,865,000. Norges Bank acquired a new position in REGENXBIO in the 4th quarter valued at about $3,474,000. Voss Capital LP purchased a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $2,573,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after buying an additional 296,700 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Stock Down 9.9 %

Shares of REGENXBIO stock traded down $0.79 during trading on Wednesday, hitting $7.14. 624,066 shares of the company were exchanged, compared to its average volume of 996,967. The firm has a 50 day moving average price of $7.25 and a 200 day moving average price of $8.06. The stock has a market capitalization of $357.58 million, a price-to-earnings ratio of -1.42 and a beta of 1.11. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $17.35.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. Analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGNX. HC Wainwright cut their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, March 17th. Morgan Stanley upped their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a report on Tuesday, March 18th. Raymond James started coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price target on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.